RUFFATTI, AMELIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.842
AS - Asia 5.870
EU - Europa 3.486
AF - Africa 1.455
SA - Sud America 1.210
OC - Oceania 151
Continente sconosciuto - Info sul continente non disponibili 67
Totale 27.081
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.119
SG - Singapore 2.115
CN - Cina 1.259
BR - Brasile 734
HK - Hong Kong 658
DE - Germania 417
VN - Vietnam 416
FI - Finlandia 379
IT - Italia 328
SE - Svezia 240
NL - Olanda 200
UA - Ucraina 198
FR - Francia 177
RU - Federazione Russa 167
PL - Polonia 157
GB - Regno Unito 145
AR - Argentina 94
IN - India 74
MX - Messico 73
JP - Giappone 69
ID - Indonesia 65
IQ - Iraq 65
CI - Costa d'Avorio 64
TR - Turchia 61
ZA - Sudafrica 60
VE - Venezuela 55
ES - Italia 53
IE - Irlanda 53
CY - Cipro 52
IR - Iran 52
PT - Portogallo 52
EC - Ecuador 51
AZ - Azerbaigian 50
MA - Marocco 49
EG - Egitto 48
PE - Perù 48
PK - Pakistan 48
PY - Paraguay 48
SA - Arabia Saudita 48
BE - Belgio 47
IL - Israele 47
NI - Nicaragua 47
MR - Mauritania 45
TT - Trinidad e Tobago 45
GH - Ghana 44
MZ - Mozambico 44
AT - Austria 43
CO - Colombia 43
CZ - Repubblica Ceca 43
DZ - Algeria 43
KR - Corea 43
RS - Serbia 43
UY - Uruguay 43
KE - Kenya 42
KG - Kirghizistan 42
YT - Mayotte 42
AE - Emirati Arabi Uniti 41
AL - Albania 41
CR - Costa Rica 41
GT - Guatemala 41
ME - Montenegro 40
NO - Norvegia 40
RO - Romania 40
SN - Senegal 40
SO - Somalia 40
AO - Angola 39
CW - ???statistics.table.value.countryCode.CW??? 39
DK - Danimarca 39
GR - Grecia 39
TH - Thailandia 39
YE - Yemen 39
BO - Bolivia 38
BY - Bielorussia 38
CH - Svizzera 38
CV - Capo Verde 38
CA - Canada 37
DJ - Gibuti 37
JO - Giordania 37
SK - Slovacchia (Repubblica Slovacca) 37
TJ - Tagikistan 37
TN - Tunisia 37
TW - Taiwan 37
UZ - Uzbekistan 37
DO - Repubblica Dominicana 36
GE - Georgia 36
JM - Giamaica 36
MD - Moldavia 36
AU - Australia 35
GA - Gabon 35
HU - Ungheria 35
MG - Madagascar 35
PH - Filippine 35
SD - Sudan 35
ZW - Zimbabwe 35
AM - Armenia 34
BZ - Belize 34
GN - Guinea 34
HN - Honduras 34
LU - Lussemburgo 34
LV - Lettonia 34
Totale 25.426
Salva come PNG Salva come JPEG
Città #
Fairfield 2.095
Woodbridge 1.312
Ashburn 1.267
Singapore 1.121
Chandler 1.034
Houston 1.034
Jacksonville 757
Wilmington 745
Seattle 742
Ann Arbor 739
Cambridge 671
Hong Kong 622
Beijing 345
Princeton 340
Boardman 321
Santa Clara 243
San Diego 212
Nanjing 157
Des Moines 145
Dong Ket 142
Medford 142
Helsinki 129
Roxbury 121
Los Angeles 120
Bytom 107
Ho Chi Minh City 100
Munich 76
Abidjan 63
Padova 63
Dearborn 58
Hanoi 55
Hefei 54
New York 54
Guangzhou 52
São Paulo 51
Baku 47
Hebei 47
Nanchang 47
Chicago 44
Managua 44
Nouakchott 41
Dakar 40
Dublin 40
Jinan 38
Shenyang 37
Accra 36
Podgorica 36
Amman 35
Dushanbe 35
Jiaxing 35
Bishkek 34
Changsha 34
Bamako 33
Conakry 33
Harare 33
Lima 33
San José 33
Tashkent 33
Montevideo 32
Praia 32
Cotonou 31
Kigali 31
Libreville 31
Nairobi 31
Phnom Penh 31
Turku 31
Castries 30
Johannesburg 30
Vienna 30
Yerevan 30
Antananarivo 29
Noumea 29
Andorra la Vella 28
Buffalo 28
Kampala 28
Kingston 28
Luanda 28
Mamoudzou 28
Niamey 28
Bridgetown 27
Limassol 27
London 27
Maputo 27
Nassau 27
Riga 27
Stockholm 27
Vientiane 27
Addis Ababa 26
Djibouti 26
Khartoum 26
Panama City 26
Tallinn 26
Willemstad 26
Minsk 25
Norwalk 25
Jeddah 24
Ouagadougou 24
Tbilisi 24
Tokyo 24
Ulan Bator 24
Totale 17.323
Salva come PNG Salva come JPEG
Nome #
Erosive osteoarthritis, psoriatic arthritis and pseudogout; a casual association? 228
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 213
Diagnosis and therapy of antiphospholipid syndrome 204
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab 204
Laboratory testing for antiphospholipid syndrome 203
Antibodies to Domain I of β2-Glycoprotein I are in Close Relation to Patients Risk Categories in Antiphospholipid Syndrome (APS) 202
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report 202
Antibody profile and clinical course in primary anti phospholipid syndrome with pregnancy morbidity 202
APS - Diagnostics and challenges for the future 198
An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay results. 197
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 197
Plasma exchange effectively removes 52- and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block. 192
Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. 190
An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. 188
Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns 186
Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study 185
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 184
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 184
The efficacy of adalimumab in psoriatic arthritis concomitant to overlapping primary biliary cholangitis and primary sclerosing cholangitis: a case report 184
A contribution to detection of anticardiolipin and anti-β2glycoprotein I antibodies: Comparison between a home-made ELISA and a fluorescence enzyme immunoassay. 179
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. 179
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 175
Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study 175
Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. 174
The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases 173
A combination therapy to treat second-degree anti-ro/la-related congenital heart block. A strategy to avoid stable third-degree heart block? 172
Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study 172
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant 171
Upgrading Therapy Strategy Improves Pregnancy Outcome in Antiphospholipid Syndrome: A Cohort Management Study 168
A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. 166
Antiphospholipid syndrome: critical analysis of the diagnostic path 164
Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study 164
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. 164
Clinical and laboratory characteristics of isolated lupus anticoagulants 164
Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification 163
Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis. 163
The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study 162
Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis. 161
Interpretation of laboratory data and need for reference laboratories. 161
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 160
A catastrophic antiphospholipid syndrome: the importance of high levels of warfarin anticoagulation. 159
The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome 159
Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome 158
Correct laboratory approach to APS diagnosis and monitoring 157
Therapeutic apheresis during pregnancy: A single center experience 157
The clinical significance of autoantibodies directed against prothrombin in primary antiphospholipid syndrome. 156
Anti-double-stranded DNA antibodies in the healthy elderly: prevalence andcharacteristics 155
Biological and clinical relevance of anti-prothrombin antibodies. 154
Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. 153
Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry 152
100 years of Aspirin in the rheumatic diseases 151
IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome. 151
Antiplatelet glycoprotein autoantibodies in patients with autoimmune diseases with and without thrombocytopenia. 150
Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block 150
Antiphosphatidylserine/prothrombin antibodies in antiphospholipid syndrome with intrauterine growth restriction and preeclampsia 150
Plasma exchange in a patient with primary antiphospholipid syndrome undergoing kidney transplantation 149
Clinical value of anti-domain I-β2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study 148
Are biological drugs safe in pregnancy? 147
Hypertension negatively affects the pregnancy outcome in patients with antiphospholipid syndrome. 146
Anti-beta(2)-glycoprotein I ELISA assay: The influence of different antigen preparations 145
Antiphospholipid syndrome and right atrial mass 145
Antiphospholipid syndrome classification criteria: comments on the letter of Swadzba and Musial 143
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. 143
Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy 142
Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort 142
Detection of lupus anticoagulant in the era of direct oral anticoagulants 141
Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients 140
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study 140
Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. 137
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 137
Detection of autoantibodies to the p200-epitope of SSA/Ro52 antigen. A comparison of two laboratory assays 136
Bedside diagnosis of two major clinical phenotypes of hypertensive disorders of pregnancy 135
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. 135
IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. 135
Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. 134
Parotid, breast, and fascial involvement in a patient who fulfilled the ACR criteria for Churg-Strauss syndrome. 134
Secondary prevention in thrombotic antiphospholipid syndrome. 134
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study 134
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study 133
Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: The PREGNANTS study 133
“Disease knowledge index” and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases 133
Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. 132
Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins 131
Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome 131
A prospective study of fifty-three consecutive calcium heparin treated pregnancies in patients with antiphospholipid antibody-related fetal loss. 130
Prevalenza e significato clinico degli anticorpi anti-catepsina G nella sclerosi sistemica. 128
Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: Report of four cases and review of the literature 128
Systemic sclerosis and aortic valve stenosis: therapeutic implications in two cases of aortic valve replacement 127
Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients 127
Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study 126
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis 125
Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis 125
The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. 125
A close relationship between infections and anti-phospholipid syndrome in a child with trisomy 21. 124
Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. 124
Unstabilized DNA breaks in lymphocytes of patients with different subsets of systemic sclerosis 124
Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. 124
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 124
Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. 122
Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are theyspecific tools for the diagnosis of aPL syndrome? 122
Totale 15.605
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.466
article - articoli 81.120
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.498
Totale 168.084
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.616 0 0 0 0 0 212 69 246 332 186 266 305
2021/20222.632 73 340 301 194 99 158 97 288 128 62 295 597
2022/20232.069 492 223 20 250 342 268 9 129 204 15 90 27
2023/2024916 42 150 125 74 68 87 47 43 30 24 112 114
2024/20254.223 22 295 247 165 559 133 197 354 342 143 676 1.090
2025/20268.090 574 1.476 2.197 2.457 1.372 14 0 0 0 0 0 0
Totale 27.212